Breaking News
April 24, 2018 - FDA Approves Intravenous Formulation of Akynzeo (fosnetupitant/palonosetron) for Chemotherapy-Induced Nausea and Vomiting
April 24, 2018 - Is Alzheimer’s caused by disruptions to the brain’s energy supply?
April 24, 2018 - Low concentrations of antibiotics can develop high antibiotic resistance in bacteria
April 24, 2018 - Imagined and real movements have similar brain mechanisms, research suggests
April 24, 2018 - Alcoholic drinks affect oral bacteria tied to diseases
April 24, 2018 - Mechanism in Non-Contact ACL Tears Similar in Men, Women
April 24, 2018 - Buprenorphine may be safer than methadone if treatment duration is longer, study suggests
April 24, 2018 - NF-κB1 gene known to drive cancer development is critical for preventing stomach cancers
April 24, 2018 - New tool helps blind, low-vision users navigate modern webpages more easily
April 24, 2018 - Vegetarian diet and Mediterranean diet close to each other in health benefits
April 24, 2018 - FSU receives $1.5 million federal grant for innovative suicide prevention research
April 24, 2018 - Health Tip: Screening for Cancer in Older Adults
April 24, 2018 - Investigators highlight potential of exercise in addressing substance abuse in teens
April 24, 2018 - Study shows people might develop dementia later and live with it for a shorter period of time
April 24, 2018 - EMBL scientists develop new illumination method to manage neuropathic pain
April 24, 2018 - New compound could offer pain-relieving properties without risk of addiction
April 24, 2018 - New drug treatment could be promising therapeutic approach for millions with asthma
April 24, 2018 - Study provides guidance on using cannabis for treatment of stress, anxiety, and depression
April 24, 2018 - By Royal approval: Queen’s Award success for Elucigene
April 24, 2018 - The role of ‘extra’ DNA in cancer evolution and therapy resistance
April 24, 2018 - Researchers identify tools that caregivers could use to detect delirium in older adults
April 24, 2018 - What to Look Out For
April 24, 2018 - Drugs prescribed for newborns vary widely between NICUs, study finds
April 24, 2018 - FM4200 pressure-resistant mass flow meter from Sensirion
April 24, 2018 - Study links past experiences with bias and avoidance of doctors in women with higher BMI
April 24, 2018 - Role of extrachromosomal pieces of DNA in cancer development and treatment resistance
April 24, 2018 - Rehabilitation technique for stroke appears beneficial for multiple sclerosis patients
April 24, 2018 - Women who find purpose and meaning in life less likely to have anxiety, study shows
April 24, 2018 - Catalyst Pharmaceuticals Announces Submission of New Drug Application for Firdapse for Treatment of Lambert-Eaton Myasthenic Syndrome
April 24, 2018 - Suicide and homicide rates show large racial disparities across US states
April 24, 2018 - Scientists develop tissue-engineered models to better understand cancer metastases
April 24, 2018 - NuProbe to commercialize Wyss Institute’s new technology to facilitate precision medicine
April 24, 2018 - Special series explores pasteurized donor human milk use for hospitalized infants
April 24, 2018 - Slight changes in patient’s position during radiotherapy may impact survival chances
April 24, 2018 - FDA Approves Tagrisso (osimertinib) as First-Line Treatment for EGFR-Mutated Non-Small Cell Lung Cancer
April 24, 2018 - After knee replacement, play on
April 24, 2018 - Contact precautions do not limit spread of drug-resistant bacteria in ICUs
April 24, 2018 - Researchers discover genetic catalysts that accelerate evolution of antibiotic resistance in bacteria
April 24, 2018 - WPI researcher launches mobile app for assessing perinatal depression in women
April 24, 2018 - Researchers identify superior blood-based biomarker for assessing sports-related concussions
April 24, 2018 - Gene Therapy Found to Be Promising for β-Thalassemia
April 24, 2018 - Bariatric surgery can lead to changes in relationship status
April 24, 2018 - GPs must embrace digital technologies to make healthcare access easier for patients
April 24, 2018 - Novel stem cell therapy may transform current paradigms for treating heart failure patients
April 24, 2018 - Maternal depression during and after pregnancy linked to poorer child neurodevelopment
April 24, 2018 - Vitamin D and magnesium supplements provide right nutritional support to athletes
April 24, 2018 - Could a Tattoo Someday Spot Your Cancer?
April 24, 2018 - Throat reflexes differ in people with tetraplegia and sleep apnea
April 24, 2018 - Study shows no increased risk of breast cancer recurrence after DIEP flap reconstruction
April 24, 2018 - Nearly three-quarters of commonly used medical scopes tainted by bacteria
April 24, 2018 - Home-based treatment program offers robust and sustained relief for IBS patients
April 24, 2018 - New IntelliCyt Cy-Clone PLUS streamlines clone ranking and selection for cell line development
April 24, 2018 - Scientists examine how specific eating patterns could help fight cancer and obesity
April 24, 2018 - Study sheds new light on how bilinguals process language
April 24, 2018 - Probiotics can improve liver health, shows study
April 24, 2018 - Study may explain how chemoresistance evolves over time in some triple-negative breast cancers
April 24, 2018 - Role of midbrain in encoding identity errors
April 23, 2018 - Salamander study provides clues for treating spinal cord injuries
April 23, 2018 - Relaxation after work could give better night’s sleep
April 23, 2018 - Loneliness on its way to becoming Britain’s most lethal condition
April 23, 2018 - Low-cost blood test for multiple myeloma can deliver same diagnostic information as bone biopsy
April 23, 2018 - Metabolic differences may contribute to postpartum weight retention in black moms
April 23, 2018 - Time-Related Deployment Factors Predict Suicide Attempt Risk
April 23, 2018 - Are newborns ugly? Research says newborns rated ‘less cute’ than older babies
April 23, 2018 - Prenatal marijuana use linked to increased chance of low birth weights
April 23, 2018 - Researchers identify target gene in P. aeruginosa infection
April 23, 2018 - New studies related to causes of liver degradation and possible treatments
April 23, 2018 - Studies offer leads for new approaches to treat neurological problems
April 23, 2018 - Promising cell study may offer new opportunities for treating Parkinson’s disease
April 23, 2018 - Gene Therapy May Be Cure for Some With Rare Blood Disorder
April 23, 2018 - Obesity impacts liver health in kids as young as eight years old
April 23, 2018 - Frequent cannabis use by young people linked to small reductions in cognitive function
April 23, 2018 - Innovative research could lead to new ways to treat, prevent cancer
April 23, 2018 - Study uncovers possible source of gender differences in migraines
April 23, 2018 - Study proves usefulness of EDX testing in diagnosis, management of neuromuscular disorders
April 23, 2018 - Hacking ‘drug trafficking’ system could increase effectiveness of diabetes treatment
April 23, 2018 - Clinical trial to examine stem cell therapy for treatment, prevention of complications after traumatic injury
April 23, 2018 - Targeted radiotherapy found to be a good option for women with early breast cancer
April 23, 2018 - Eating fish could prevent Parkinson’s disease
April 23, 2018 - Philips showcases dedicated radiation oncology solutions at ESTRO 2018
Pacira Announces FDA Approval of Exparel as a Nerve Block to Produce Regional Analgesia

Pacira Announces FDA Approval of Exparel as a Nerve Block to Produce Regional Analgesia

image_pdfDownload PDFimage_print

PARSIPPANY, N.J., April 06, 2018 (GLOBE NEWSWIRE) — Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) to broaden the use of Exparel (bupivacaine liposome injectable suspension) to include administration via interscalene brachial plexus block to produce postsurgical regional analgesia. With this approval, Exparel is the first long-acting, single-dose nerve block available for patients undergoing upper extremity surgeries, such as total shoulder arthroplasty or rotator cuff repair.

“Brachial plexus blocks are emerging as a mainstay of postsurgical pain control for upper extremity procedures, and are well positioned to comprise more than 60 percent of all regional nerve block procedures within the next two years, ” said Dave Stack, chairman and chief executive officer at Pacira Pharmaceuticals. “In line with our corporate mission, we are very gratified to offer clinicians and patients another option for achieving long-lasting non-opioid pain control with Exparel, and to provide an increased ability to transition procedures commonly thought of as inpatient to the ambulatory setting.”

Since its initial approval in 2011 for single-dose infiltration into the surgical site, more than 3.75 million patients have been treated with Exparel in the post-marketing setting. The expansion of the Exparel label to now also include interscalene brachial plexus nerve block allows clinicians to potentially eliminate the need for cumbersome catheters and pumps traditionally used to extend the duration of regional analgesia.

“There is a critical need in the postsurgical setting for non-opioid options that turn off pain at the surgical site and reduce the need for opioids,” said Jeffrey Gadsden, MD, Chief of Orthopaedics, Plastics, and Regional Anesthesiology and Associate Professor of Anesthesiology at Duke University School of Medicine. “The ability to provide effective regional analgesia with a single dose of Exparel is a tremendous victory for patients and advances the imperative need for low- or no-opioid pain management strategies.”

The sNDA approval was based on positive data from a Phase 3 study of Exparel in brachial plexus block for shoulder surgeries, in which Exparel demonstrated statistical significance for the primary endpoint of cumulative pain scores over 48 hours as measured by the area under the curve (P

The safety profile for Exparel in the interscalene brachial plexus nerve block study was consistent with the previously reported safety profile of Exparel in wound infiltration, and also with the profile of bupivacaine when used as a brachial plexus nerve block.

The study randomized 156 patients across 17 sites in a 1:1 ratio to receive a single dose of either Exparel 133 mg in 10 mL expanded in volume with 10 mL of normal saline for a total volume of 20 mL or placebo 20 mL. Exparel was administered as a single-dose brachial plexus block under ultrasound guidance at least one hour prior to surgery. All patients were eligible to receive postsurgical rescue opioids upon request for pain control.

About Pacira

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company dedicated to advancing and improving postsurgical outcomes for acute care practitioners and their patients. The company’s flagship product, Exparel® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. Exparel utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.

About Exparel

Exparel (bupivacaine liposome injectable suspension) is indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. The product combines bupivacaine with DepoFoam®, a proven product delivery technology that delivers medication over a desired time period. Exparel represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting. By utilizing the DepoFoam platform, a single dose of Exparel delivers bupivacaine over time, providing significant reductions in cumulative pain scores with up to a 78 percent decrease in opioid consumption; the clinical benefit of the opioid reduction was not demonstrated. Additional information is available at www.EXPAREL.com.

Forward Looking Statements

Any statements in this press release about the company’s future expectations, plans, outlook and prospects, and other statements containing the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,” “may” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to: the success of the company’s sales and manufacturing efforts in support of the commercialization of EXPAREL; the rate and degree of market acceptance of EXPAREL and the company’s other products; the size and growth of the potential markets for EXPAREL and the company’s ability to serve those markets; the company’s plans to expand the use of EXPAREL to additional indications and opportunities, and the timing and success of any related clinical trials; the related timing and success of United States Food and Drug Administration supplemental New Drug Applications; the outcome of the U.S. Department of Justice inquiry; the company’s plans to evaluate, develop and pursue additional DepoFoam-based product candidates; clinical trials in support of an existing or potential DepoFoam-based product; the company’s commercialization and marketing capabilities; the company’s and Patheon UK Limited’s ability to successfully and timely construct dedicated EXPAREL manufacturing suites; and other factors discussed in the “Risk Factors” of the company’s most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2017 and in other filings that the company periodically makes with the SEC. In addition, the forward-looking statements included in this press release represent the company’s views as of the date of this press release. Important factors could cause actual results to differ materially from those indicated or implied by forward-looking statements, and as such the company anticipates that subsequent events and developments will cause its views to change. However, while the company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date of this press release.

Source: Pacira Pharmaceuticals, Inc.

Posted: April 2018

Related Articles:

Exparel (bupivacaine liposome) FDA Approval History

Tagged with:

About author

Related Articles